Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refractory Multiple Myeloma Treatment

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Meletios Dimopoulos
October 17, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

26:48
Bristol Myers Squibb Hematology

Expert Discusses Data for a RRMM Regimen

Feat. K. Shain

Related Content

AUTOPLAY
SOHO 3rd Italian Conference

SOHO 3rd Italian Conference

Mon, Sep 27, 2021
14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can …

Feat. T. Martin
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Se…

25:24
Extracellular Vesicles and Their Role in Patients With Multiple Myeloma

Biologically Based Therapies for MM: Surveying Novel Options

Feat. K. Anderson
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
04:41
Joshua Richter

Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Trials

06:31
2nd SOHO Italian Conference

Treatment Options for the R/R MM Patients: A Review of the Current Data

Feat. K. Anderson
12:53
2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli
23:44
UAB Hematology Review 2021

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triplets, Su…

Feat. K. Godby
18:43
7th Eurasian Hematology Oncology Summit

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121?…

Feat. E. Terpos
05:33
Baptist Health South Florida CME

2021 Advancements in Blood Cancers: Blinatumomab in ALL, Pre-ASCT Inductio…

Feat. G. Koehne
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/R …

06:12
Indy Hematology Review

Targeting Mutations in Myeloma with Venetoclax and Development of the Firs…

Feat. K. Anderson
10:20
Ambuga Badari

Ochsner Health Update on R/R MM Options: Current Landscape and Future Dire…

19:41
Peter Voorhees

Approach to the Patient with Refractory & Multiple Relapsed Multiple M…

21:36
8th Eurasian Hematology Oncology Summit

CAR-T Cell Therapy for Multiple Myeloma

Feat. E. Terpos
10:30
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)

Next Questions in Myeloma: Biology, Smoldering Myeloma, High-risk, MRD, an…

Feat. S. Jagannath
15:02
Krina Patel

Clinical Trials in Myeloma in 2018